12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RVX-208: Completed Phase IIb enrollment

Resverlogix said it completed enrollment in the double-blind, placebo-controlled, international Phase IIb ASSURE trial evaluating twice-daily 100 mg oral RVX-208 for 26 weeks in about 310 patients...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >